CompletedPhase 4

Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)

China1,022 participantsStarted 2022-07-08

Plain-language summary

The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old; * Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset; * NIHSS ≤ 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination; * Premorbid mRS ≤ 1; * Signed informed consent. Exclusion Criteria: * Premorbid mRS≥2; * Uncontrolled severe hypertension (systolic pressure \>180 mmHg or diastolic pressure \>110 mmHg after drug treatment); * Antithrombotic treatment within 24 hours before randomization; * Significant dysphagia and inability to take the experimental drug orally; * Allergy or contraindication to study drugs; * Comorbidity with any serious diseases and life expectancy is less than half a year; * Participating in other clinical trials within three months; * Patients not suitable for this clinical study considered by researcher

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The proportion of excellent prognosis

Timeframe: Day 90

Trial details

NCT IDNCT05193071

SponsorGeneral Hospital of Shenyang Military Region

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-25

View on ClinicalTrials.gov More Ischemic Stroke trials